Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

Historically, the North American Brain Tumor Consortium used 6-month progression-free survival (PFS6) as the primary outcome for recurrent glioma phase II clinical trials. In some trials, a subset of patients received the trial treatment before surgery to assess tumor uptake and biological activity....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Clarke†, Jennifer L., Ennis†, Michele M., Yung, W. K. Alfred, Chang, Susan M., Wen, Patrick Y., Cloughesy, Timothy F., DeAngelis, Lisa M., Robins, H. Ian, Lieberman, Frank S., Fine, Howard A., Abrey, Lauren, Gilbert, Mark R., Mehta, Minesh, Kuhn, John G., Aldape, Kenneth D., Lamborn, Kathleen R., Prados, Michael D.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2011
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3177665/
https://ncbi.nlm.nih.gov/pubmed/21813511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nor110
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados